Cure8 news brief
Cure8 news brief
Mapping 3D genome contacts in rare gut immune cells connects Crohn’s disease genetic risk variants to specific genes and pathways, which can clarify disease mechanisms and guide future drug-target research. The study nominates new genes (including CLN3) that may influence ILC3 inflammatory function.
Researchers in IBD genetics and immunology; translational scientists; clinicians interested in Crohn’s disease biology; patients curious about research on genetic causes of IBD.
Researchers used a low-input 3D genome mapping method (mini-Capture Hi-C / mini-PCHi-C) to profile chromatin contacts in rare ILC3 immune cells and link enhancer variants to target genes.
Applying these maps to Crohn’s disease GWAS signals, the team nominated over 100 genes in ILC3s that may be affected by disease-associated regulatory variants, including known immune genes and previously unlinked genes such as CLN3.
The study included experimental validation suggesting CLN3 influences ILC3 inflammatory activity, but the article does not present clinical results or therapeutic recommendations.
This is a basic-science study reported in a press release about a Nature Genetics paper. While it includes lab validation of one gene’s role in ILC3s, it does not provide clinical evidence that would affect treatment. Further studies are needed to confirm causality and therapeutic potential.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.